How long should we maintain anti-HER2 therapy for metastatic breast cancer patients with complete remission?

Bekir Hacioglu; Serkan Akin; Taner Babacan; Ali R Sever; Kadri Altundag

doi:10.2217/fon.15.165

How long should we maintain anti-HER2 therapy for metastatic breast cancer patients with complete remission?

Future Oncol. 2015;11(20):2799-801. doi: 10.2217/fon.15.165. Epub 2015 Sep 7.

Authors

Bekir Hacioglu¹, Serkan Akin¹, Taner Babacan¹, Ali R Sever², Kadri Altundag¹

Affiliations

¹ Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
² Department of Radiology, Hacettepe University School of Medicine, Ankara, Turkey.

PMID: 26344497
DOI: 10.2217/fon.15.165

No abstract available

Keywords: HER2 positive; breast; cancer; complete remission; long term; maintenance therapy; metastatic; progression; trastuzumab; treatment duration.

Publication types

Editorial

MeSH terms

Antineoplastic Agents / administration & dosage*
Breast Neoplasms / drug therapy*
Breast Neoplasms / genetics
Breast Neoplasms / pathology
Female
Humans
Receptor, ErbB-2 / genetics
Trastuzumab / administration & dosage*

Substances

Antineoplastic Agents
Receptor, ErbB-2
Trastuzumab